T Powles

Summary

Affiliation: Barts and The London NHS Trust
Country: UK

Publications

  1. ncbi request reprint The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis
    T Powles
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Ann Oncol 19:443-7. 2008
  2. ncbi request reprint Multicenter study of human immunodeficiency virus-related germ cell tumors
    T Powles
    Chelsea and Westminster Hospital, London, United Kingdom
    J Clin Oncol 21:1922-7. 2003
  3. ncbi request reprint A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
    J Shamash
    The Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Ann Oncol 18:925-30. 2007
  4. ncbi request reprint Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over
    Daniel M Berney
    Department of Histopathology, Barts, The London School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London, UK
    Mod Pathol 21:54-9. 2008
  5. doi request reprint Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection
    Thomas Powles
    Department of Medical Oncology, St Bartholomew s Hospital, Little Brittain, London EC1A7BE, United Kingdom
    J Clin Oncol 27:884-90. 2009
  6. doi request reprint Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Thomas Powles
    Thomas Powles, Queen Mary University of London, London Christy Ralph, University of Leeds, Leeds Janet E Brown, University of Sheffield, Sheffield Robert E Hawkins, University of Manchester, Manchester, United Kingdom Mark R Lackner, Wei Lin, Bridget O Keeffe, Yulei Wang, Shan Lu, Jill M Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A Ware, Genentech, South San Francisco, CA Robert J Motzer, Memorial Sloan Kettering Cancer Center, New York, NY Brian I Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Bernard Escudier, Institut Gustave Roussy, Villejuif Alain Ravaud, Hospital Saint André, Bordeaux Stéphane Oudard, University Paris Descartes, Paris, France Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain and Michael D Staehler
    J Clin Oncol 34:1660-8. 2016
  7. doi request reprint Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients
    Thomas Powles
    Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London EC1A 7BE, UK Electronic address
    Eur J Cancer 51:1293-302. 2015
  8. pmc The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
    Thomas Powles
    Department of Medical Oncology, St Bartholomew s Hospital, London, United Kingdom
    Onco Targets Ther 1:35-9. 2008
  9. pmc Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial
    Darren R Feldman
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York USA
    J Cancer 2:374-7. 2011
  10. doi request reprint Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy
    Thomas Powles
    Barts Cancer Institute, Barts Experimental Cancer Medicine Centre, Bart and the London NHS Trust, London, United Kingdom
    Clin Genitourin Cancer 10:213-8. 2012

Detail Information

Publications55

  1. ncbi request reprint The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis
    T Powles
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Ann Oncol 19:443-7. 2008
    ..The use of adjuvant carboplatin in the management of stage I seminoma of the testis has been limited by the lack of long-term data. In this study, we address this issue for the first time...
  2. ncbi request reprint Multicenter study of human immunodeficiency virus-related germ cell tumors
    T Powles
    Chelsea and Westminster Hospital, London, United Kingdom
    J Clin Oncol 21:1922-7. 2003
    ..Testicular germ cell tumors (GCT) occur at increased frequency in men with human immunodeficiency virus (HIV). This multicenter study addresses the characteristics of these tumors...
  3. ncbi request reprint A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
    J Shamash
    The Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Ann Oncol 18:925-30. 2007
    ..We investigated the role of irinotecan, paclitaxel and oxaliplatin (IPO) followed by topotecan-based high-dose therapy in responding patients, in this patient population...
  4. ncbi request reprint Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over
    Daniel M Berney
    Department of Histopathology, Barts, The London School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London, UK
    Mod Pathol 21:54-9. 2008
    ..We conclude that germ cell tumours, in man aged 60 years or above, present at a later stage than in younger men, and although most are seminomas, non-seminomatous tumours may occur with a wide spectrum of morphology...
  5. doi request reprint Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection
    Thomas Powles
    Department of Medical Oncology, St Bartholomew s Hospital, Little Brittain, London EC1A7BE, United Kingdom
    J Clin Oncol 27:884-90. 2009
    ..The effect of highly active antiretroviral therapy (HAART) on the incidence of non-AIDS-defining cancers (NADCs) is unclear...
  6. doi request reprint Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Thomas Powles
    Thomas Powles, Queen Mary University of London, London Christy Ralph, University of Leeds, Leeds Janet E Brown, University of Sheffield, Sheffield Robert E Hawkins, University of Manchester, Manchester, United Kingdom Mark R Lackner, Wei Lin, Bridget O Keeffe, Yulei Wang, Shan Lu, Jill M Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A Ware, Genentech, South San Francisco, CA Robert J Motzer, Memorial Sloan Kettering Cancer Center, New York, NY Brian I Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Bernard Escudier, Institut Gustave Roussy, Villejuif Alain Ravaud, Hospital Saint André, Bordeaux Stéphane Oudard, University Paris Descartes, Paris, France Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain and Michael D Staehler
    J Clin Oncol 34:1660-8. 2016
    ....
  7. doi request reprint Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients
    Thomas Powles
    Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London EC1A 7BE, UK Electronic address
    Eur J Cancer 51:1293-302. 2015
    ..Our data support the current guidelines on regular liver chemistry tests after initiation of pazopanib, especially during the first 9 or 10weeks, and also demonstrate the safety of rechallenge with pazopanib. ..
  8. pmc The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
    Thomas Powles
    Department of Medical Oncology, St Bartholomew s Hospital, London, United Kingdom
    Onco Targets Ther 1:35-9. 2008
    ..As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therapy, we report on the outcome of 11 patients treated with IPM after sunitinib failure...
  9. pmc Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial
    Darren R Feldman
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York USA
    J Cancer 2:374-7. 2011
    ..It is hoped that this large study will conclusively resolve the uncertainty which currently exists...
  10. doi request reprint Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy
    Thomas Powles
    Barts Cancer Institute, Barts Experimental Cancer Medicine Centre, Bart and the London NHS Trust, London, United Kingdom
    Clin Genitourin Cancer 10:213-8. 2012
    ..These include scenarios such as a mixed response to therapy. For selected patients at favorable risk, active surveillance may be feasible; however, strict monitoring is required...
  11. doi request reprint The effect of sunitinib on immune subsets in metastatic clear cell renal cancer
    Thomas Powles
    St Bartholomew Hospital, London, UK
    Urol Int 86:53-9. 2011
    ..It is associated with leucopenia; however, its effects on specific immune cell subsets are unclear. Alterations in immune cell subsets may contribute to tumour progression...
  12. doi request reprint Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
    T Powles
    Centre for Experimental Cancer Medicine, St Bartholomew s Hospital, London, UK
    Ann Oncol 22:815-20. 2011
    ..We investigate their expression in mRCC patients treated with sunitinib and correlate their expression with plasma growth factor levels [insulin-like growth factor (IGF)-1]...
  13. ncbi request reprint Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?
    Thomas Powles
    St Bartholomew s Hospital, Department of Medical Oncology, London, UK
    Expert Rev Anticancer Ther 6:1553-8. 2006
    ..It also attempts to predict future areas of importance in the management of these patients in the era of highly active antiretroviral therapy...
  14. doi request reprint Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
    Thomas Powles
    St Bartholomew s Hospital, Barts and The London NHS Trust, Charterhouse Square, London EC1A7BE, UK
    Hematol Oncol Clin North Am 25:517-27,viii. 2011
    ..This article addresses the risks and benefits of each approach...
  15. doi request reprint A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
    T Powles
    Experimental Cancer Centre, Barts Cancer Institute, Queen Mary, University of London, St Bartholomew s Hospital, London, UK
    Ann Oncol 24:2098-103. 2013
    ..The role of intermittent therapy is under investigation. Preclinical data raise concerns about this approach...
  16. pmc The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
    T Powles
    Department of Medical Oncology, St Bartholomew s Hospital
    Ann Oncol 22:1041-7. 2011
    ..The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated...
  17. pmc A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia
    T Powles
    Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease Centre, Hammersmith Hospitals Campus of Imperial College London, London, UK
    Br J Cancer 96:732-7. 2007
    ..01)). The outcome of patients with relapsed GTN is good. However, patients with primary chemo-refractory disease do poorly and novel therapies are required for this group of patients...
  18. doi request reprint The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease
    T Powles
    Department of Medical Oncology, Barts and the London Medical School, London, UK
    Ann Oncol 20:775-9. 2009
    ..In HIV cohorts with access to highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) is falling; however, the incidence of multicentric Castleman's disease (MCD) in HIV has not previously been described...
  19. doi request reprint Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience
    S Gillessen
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Ann Oncol 21:1589-93. 2010
    ..There is a lack of published data supporting its use. The data presented here specifically address this issue for the first time...
  20. pmc A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
    J Shamash
    St Bartholomew s Hospital, 7th Floor, Gloucester House, Little Britain, UK
    Br J Cancer 104:620-8. 2011
    ....
  21. ncbi request reprint An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia
    A M Young
    Dept of Oncology, Chelsea and Westminster Hospital, London, UK
    J HIV Ther 12:68-71. 2007
  22. ncbi request reprint Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus
    T Powles
    Department of Oncology, Chelsea and Westminster Hospital, London, UK
    J Laryngol Otol 118:207-12. 2004
    ..All but one of the patients died of cancer with a median survival of 28 months. Head and neck cancer occurs more frequently in HIV. It is an aggressive disease and EBV may play a role in its pathogenesis...
  23. pmc Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
    N Bharwani
    Department of Radiology, Barts Health NHS Trust, St Bartholomew s Hospital, King George V Building, West Smithfield, London EC1A 7BE, UK
    Br J Cancer 110:616-24. 2014
    ..We prospectively assess diffusion-weighted and multiphase contrast-enhanced (MCE) MR imaging (MRI) as markers of outcome...
  24. pmc Sunitinib and other targeted therapies for renal cell carcinoma
    T Powles
    Department of Medical Oncology, St Bartholomew s Hospital London, Barts and The London NHS Trust, Charterhouse Square, London, UK
    Br J Cancer 104:741-5. 2011
    ..Finally, we will describe the major areas of clinical research that will report over the next few years...
  25. pmc GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
    J Shamash
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Br J Cancer 97:308-14. 2007
    ..GAMEC is a novel intensive regimen for this group of patients producing encouraging responses, although with significant toxicity. For those in whom it fails, further therapy is still possible with durable responses being seen...
  26. ncbi request reprint Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan
    C L Davies
    Department of Oncology, Imperial College School of Science, Medicine and Technology, Chelsea and Westminster Hospital, London, United Kingdom
    AJNR Am J Neuroradiol 28:1988-90. 2007
    ..We investigated the utility of brain CT in determining the outcome of leptomeningeal disease, despite MR imaging being the gold standard...
  27. pmc A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
    J Shamash
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Br J Cancer 98:22-4. 2008
    ..0 months vs 3.7 months P=0.003). Eight out of 12 patients who did not respond to diethylstilbestrol before chemotherapy did so post chemotherapy. Re-induction of hormone sensitivity can occur after chemotherapy in AIPC...
  28. doi request reprint Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
    J C Welti
    Tumour Angiogenesis Group, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Oncogene 30:1183-93. 2011
    ..We suggest that therapeutic strategies designed to simultaneously target both VEGF and FGF2 signalling may prove more efficacious than sunitinib in renal cancer patients whose tumours express FGF2...
  29. ncbi request reprint Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study
    J Shamash
    St Bartholomew s Hospital, London, United Kingdom Imperial College, London, United Kingdom St Bartholomew s Hospital, London, United Kingdom St Barthlomew s Hospital, London, United Kingdom
    J Clin Oncol 29:2573. 2011
    ..Fixed doses of high dose lenograstim may facilitate predictable recovery following WBR. Alkylating drugs have shown activity in CRPC. We investigated the role of melphalan and WBR in metastatic CRPC...
  30. ncbi request reprint Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer
    T Powles
    St Bartholomew s Hospital, London, United Kingdom Guy s and St Thomas Hospital, London, United Kingdom University College Hospital, London, United Kingdom Mount Vernon Cancer Centre, Northwood, United Kingdom
    J Clin Oncol 29:301. 2011
    ..Three sequential scans were performed to determine the importance of the timing of scans...
  31. ncbi request reprint Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations
    J Stebbing
    Departments of Oncology and HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Ann Oncol 14:1660-6. 2003
    ..Cytokines measured included tumour necrosis factor-alpha (TNF-alpha), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and the interleukins IL-2, -6 and -12...
  32. pmc Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era
    Douglas C Macdonald
    Chelsea and Westminster Hospital, London, United Kingdom
    World J Gastroenterol 14:1657-63. 2008
    ..Once HCC develops, there is growing evidence that HIV co-infection should not preclude conventional therapeutic strategies, including liver transplantation...
  33. ncbi request reprint The increasing incidence of HIV-associated multicentric Castlemans disease
    A Bazeos
    St Bartholomew s Hospital, London, United Kingdom Imperial College, London, United Kingdom Chelsea and Westminster Hospital, London, United Kingdom
    J Clin Oncol 26:7085. 2008
    ..In HIV cohorts with access to highly active antiretroviral therapy (HAART) the incidence of KS is falling; however the incidence of MCD in this setting has not previously been described...
  34. ncbi request reprint Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma
    M Bower
    Chelsea and Westminster Hospital, London, United Kingdom St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 26:8582. 2008
    ..8582 Background: Late effects of chemotherapy on immunological parameters in AIDS-related systemic NHL have not been described...
  35. ncbi request reprint Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer
    A M Waterston
    Department of Cancer Medicine, Faculty of Medicine, Imperial College School of Medicine, London, W12 0HS, UK
    Cancer Immunol Immunother 54:848-57. 2005
    ..However, since the antibodies were only able to cross-react with partly denatured TNFalpha, evaluation of safety and tumour responses to the TNFalpha vaccine was compromised...
  36. doi request reprint Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis
    N Murugaesu
    Department of Medical Oncology, St Bartholomew s Hospital, Gloucester House, West Smithfield, London, EC1A 7BE, UK
    Osteoporos Int 20:1627-30. 2009
    ..This study investigates the incidence of osteoporosis in 39 testis cancer patients with follow-up from 5 to 28 years. There was no increased incidence of osteoporosis. These initial data are reassuring but require further investigation...
  37. doi request reprint Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy
    Marco Gerlinger
    Department of Medical Oncology, St Bartholomew s Hospital, Barts and the London School of Medicine and Dentistry, West Smithfield, London EC1A 7BE, UK
    Eur J Cancer 46:2913-8. 2010
    ..This study determines whether lactate dehydrogenase (LDH) or established prognostic models can predict the outcome of recurrent GCTs treated with dose dense cisplatin-based chemotherapy...
  38. doi request reprint A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
    T Powles
    Department of Medical Oncology, The Royal Free NHS Foundation Trust, London Barts Cancer Institute, CRUK Experiment Cancer Medicine Centre, London
    Ann Oncol 27:880-6. 2016
    ..This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib...
  39. ncbi request reprint Non-AIDS-defining cancers in people with HIV infection: a sleeping giant?
    Thomas Powles
    Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London
    J HIV Ther 11:57-60. 2006
  40. ncbi request reprint Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival
    M Gerlinger
    St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 26:16102. 2008
    ..In this study we analysed the influence of castration status at the end of chemotherapy on survival outcome...
  41. pmc The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours
    T Powles
    Charing Cross Gestational Trophoblastic Centre, London, UK
    Br J Cancer 95:1145-7. 2006
    ..The interval between antecedent pregnancy and diagnosis in high-risk GTT is of prognostic significance. This gives some insight into the pathogenesis of the disease...
  42. ncbi request reprint A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial
    S P Lerner
    Baylor College of Medicine, Houston, TX St Bartholomew s Hospital, London, United Kingdom Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN Indiana University School of Medicine, Indianapolis, IN Department of Pathology and Laboratory Medicine, Indiana University Medical Center, Indianapolis, IN Department of Histopathology, St Bartholomew s Hospital, London, United Kingdom Michiana Hematology Oncology PC, South Bend, IN South Bend Medical Foundation, South Bend, IN The Methodist Hospital, Houston, TX Baylor College of Medicine US Oncology Research, Houston, TX
    J Clin Oncol 29:e15173. 2011
    ..A phase II study of neoadjuvant cisplatin (C), gemcitabine (G), and the multi-targeted VEGFR tyrosine kinase inhibitor sunitinib (S) in miUC patients was conducted to determine the clinical efficacy and safety of the CGS regimen...
  43. ncbi request reprint Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
    C Blick
    The Churchill Hospital, Oxford, United Kingdom St James s University Hospital, Leeds, United Kingdom Oxford Radcliffe Hospitals, Oxford, United Kingdom St James s University Hospital, Harrogate, United Kingdom St Bartholomew s Hospital, London, United Kingdom University of Oxford, Oxford, United Kingdom Yorkshire Deanery, St James s University Hospital, Leeds, United Kingdom Medical Oncology Department, University of Oxford, Oxford, United Kingdom St James s Institute of Oncology, Leeds, United Kingdom
    J Clin Oncol 29:235. 2011
    ..We present data regarding its use as NAC in MIBC patients...
  44. ncbi request reprint Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
    D H Josephs
    Guy s Hospital, London, United Kingdom Baylor Sammons Cancer Center, Dallas, TX The Royal Marsden Hospital, London, United Kingdom Dana Farber Cancer Institute, Boston, MA Brigham and Women s Hospital, Harvard Medical School, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Barts and The London Hospital, London, United Kingdom
    J Clin Oncol 27:5109. 2009
    ....
  45. ncbi request reprint A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines
    J Perry
    St Bartholomew s Hospital, London, United Kingdom GlaxoSmithKline, London, United Kingdom
    J Clin Oncol 26:14618. 2008
    ..In this work investigate interactions between lapatinib and cisplatin or SN-38 (the active metabolite of irinotecan) in cisplatin sensitive (testis cancer) and resistant cancer cell lines...
  46. ncbi request reprint Overview of the main outcomes in breast-cancer prevention trials
    J Cuzick
    Cancer Research UK, London, UK
    Lancet 361:296-300. 2003
    ..Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results...
  47. pmc Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
    J Y Pierga
    Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
    Br J Cancer 96:341-51. 2007
    ..2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages...
  48. pmc The prognostic significance of transforming growth factors in human breast cancer
    P A Murray
    Department of Medical Oncology, St Georges Hospital, London, UK
    Br J Cancer 67:1408-12. 1993
    ..018). EGFR levels did not predict for early relapse or survival. TGF alpha mRNA levels were measured in 104 patients, no correlation was seen tumour size, node status, Er status, or clinical outcome...
  49. ncbi request reprint Prostate cancer in HIV-positive individuals: what we know and what we don't
    Zoe Walters
    Dept of Medical Oncology, St Bartholomew s Hospital, London, UK
    J HIV Ther 12:66-7. 2007
  50. ncbi request reprint Germ-cell tumors
    Jonathan Shamash
    N Engl J Med 357:1771-2; author reply 1773-4. 2007
  51. ncbi request reprint Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  52. ncbi request reprint HIV-associated Castleman's disease: from case reports to evidence
    Alexandra Bazeos
    J HIV Ther 12:61-2. 2007
  53. ncbi request reprint Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity
    Wai Man Liu
    New Drug Study Group, Barry Reed Oncology Laboratory, St Bartholomew s Hospital, London, UK
    Oncogene 23:981-90. 2004
    ..Conversely, our results also suggest that GFs are safe to use in chemotherapeutic regimens if the cancer cells do not overexpress the particular receptor...
  54. ncbi request reprint HIV and the risk of lung cancer
    Thomas Powles
    J Clin Oncol 22:1348-9; author reply 1349-50. 2004
  55. ncbi request reprint A comparison of the platinum analogues in bladder cancer cell lines
    Thomas Powles
    Barry Reed Oncology Laboratory, Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Urol Int 79:67-72. 2007
    ..Therefore, this study compares the efficacy of oxaliplatin with cisplatin and carboplatin, which are both used widely in this tumour type, in bladder cancer cell lines...